Skip to content

Intervening on Opioid Use and Loneliness

Addressing Loneliness as a Therapy Target Among Individuals Using Opioids

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06458335
Enrollment
300
Registered
2024-06-13
Start date
2024-09-19
Completion date
2029-06-30
Last updated
2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Loneliness, Opioid Use Disorder, Social Isolation

Brief summary

This study aims to enroll 300 participants who will be assigned to one of three 3 groups. Each group will receive an intervention lasting 6, weekly sessions of 40-60 minutes. Eligibility include having an opioid use disorder and reporting loneliness or feeling alone or disconnected.

Detailed description

Individuals (n = 300) with an opioid use disorder reporting loneliness will be randomized to either (1) therapist-delivered cognitive-behavioral therapy for perceived social isolation, (2) therapist-delivered Health Education, or (3) self-guided Health Education. Loneliness, opioid and other substance use, the amount of social interactions, social support, and mental and physical health factors prior to starting the treatment, after completing the treatment, and 1, 3, and 6 months following the treatment will be assessed to see how well they work compared to each other.

Interventions

6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use

BEHAVIORALHealth Education

Health education provides information on the importance and benefits of and guidelines for living a health lifestyle

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Medical University of South Carolina
CollaboratorOTHER
Ohio State University
CollaboratorOTHER
University of Rochester
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must be 18+ * understand English -have internet access- * screen positive for an opioid use disorder * screen positive for elevated loneliness

Exclusion criteria

* does not understand consent * does not have consistent access to a phone and internet

Design outcomes

Primary

MeasureTime frameDescription
Mean change in number of days of opioid useBaseline to 6 monthsParticipants will complete a calendar indicating the type and frequency of drug use.
Mean change in lonelinessBaseline to 6 monthsLoneliness will be measured using the UCLA Loneliness Scale. A 20-item scale designed to measure one's subjective feelings of loneliness as well as feelings of social isolation. Participants rate each item as 1 (never), 2 (rarely), 3 (sometimes) or 4 (often). The scores range from 20-80 with higher scores indicating worse outcome.

Secondary

MeasureTime frameDescription
mean change in social interactionsBaseline to 6 monthsDuke Social Support Index assesses several domains of perceived social support, including social network size, social interaction, social satisfaction, and instrumental social support. Higher scores indicate a higher quality of social interactions. Scores range from 0 to 37.
Mean change in depressionBaseline to 6 monthsDepression will be measured using the PROMIS tool. The scores range from 4-20 with higher scores indicating worse outcome.
Mean change in anxietyBaseline to 6 monthsAnxiety will be measured using the PROMIS tool. The scores range from 4-20 with higher scores indicating worse outcome.

Countries

United States

Contacts

Primary ContactLisham Ashrafioun, PhD
lisham_ashrafioun@urmc.rochester.edu585-430-2026

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026